Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Outlook Therapeutics
Outlook Therapeutics
FDA Denies Outlook’s Wet AMD Bid, Issues Complete Response Letter
BioSpace
Wed, 08/30/23 - 11:01 am
Outlook Therapeutics
ONS-5010
wet age-related macular degeneration
FDA
Microcap's effort to take on Eylea with Avastin biosimilar faces significant FDA roadblock
Endpoints
Tue, 05/31/22 - 10:51 am
Outlook Therapeutics
Avastin
biosimilars
wet age-related macular degeneration
Roche
bevacizumab
Outlook heads to regulators with eye-friendly Avastin
EP Vantage
Wed, 08/4/21 - 10:53 am
Outlook Therapeutics
Avastin
age-related macular degeneration
FDA
Lucentis
Outlook Therapeutics Files for $57 Million Offering
CP Wire
Thu, 02/21/19 - 11:58 am
Outlook Therapeutics
wet age-related macular degeneration
Outlook Therapeutics Files for $57 Million Offering
Thu, 02/21/19 - 10:49 am
Outlook Therapeutics